# Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

> **NCT04100694** · — · APPROVED_FOR_MARKETING · sponsor: **Merus B.V.**

## Conditions studied

- NRG1 Fusion
- Pancreatic Cancer
- Non Small Cell Lung Cancer
- Solid Tumor, Unspecified, Adult
- Prostate Cancer
- Head and Neck Cancer
- Colorectal Cancer
- Breast Cancer
- Cholangiocarcinoma
- Renal Cell Carcinoma
- Unknown Primary Tumors

## Interventions

- **DRUG:** MCLA-128

## Key facts

- **NCT ID:** NCT04100694
- **Lead sponsor:** Merus B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04100694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04100694, "Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04100694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*